Peel Hunt Limited Reiterates Spirax Group (SPXSF) Buy Recommendation

Peel Hunt Limited reiterated a Buy recommendation for Spirax Group (OTCPK:SPXSF) on November 13, 2025, despite an average one-year analyst price target of $102.79, which implies a 10.62% downside from its latest closing price of $115.00. The company projects annual revenue of $1,961 million, an 18.10% increase, and non-GAAP EPS of $4.48. Institutional sentiment remains robust, with 247 funds holding positions, and total shares owned by institutions increasing by 4.56% in the last quarter, alongside a 3.15% rise in average portfolio weight.

Analysis

Peel Hunt Limited reiterated a "Buy" recommendation for Spirax Group (SPXSF) on November 13, 2025, despite an average one-year price target of $102.79, which implies a 10.62% downside from its latest reported closing price of $115.00. This suggests a potential focus on long-term value or fundamental strength over immediate valuation. The company projects robust annual revenue of $1,961 million, representing an 18.10% increase, alongside a non-GAAP EPS of $4.48.

Institutional sentiment appears broadly positive, with 247 funds reporting positions, marking a 1.23% increase in owners over the last quarter. Total shares owned by institutions grew by 4.56% to 11,407K shares in the last three months, and the average portfolio weight dedicated to SPXSF increased by 3.15%. This indicates a net inflow of institutional capital into the stock.

However, a closer look at individual institutional activity reveals mixed conviction; while Invesco Oppenheimer International Small-Mid Company Fund significantly increased its allocation by 23.10% and share count by 21.98%, other large holders like VGTSX and VTMGX decreased their portfolio allocations by 0.88% and 9.27% respectively, despite minor increases in their shareholdings. This divergence suggests varied strategic positioning among major institutional investors regarding SPXSF.

Key Decisions for Investors

• Investors should carefully weigh the analyst's "Buy" recommendation against the implied 10.62% downside from the average price target, focusing on the long-term growth prospects indicated by the 18.10% projected revenue increase.
• Monitor the sustainability of the projected $1,961MM revenue and $4.48 non-GAAP EPS, as these fundamental strengths likely underpin the positive rating despite current valuation concerns.
• Observe future institutional ownership filings for continued accumulation trends, particularly noting the nuanced allocation adjustments among key funds which reflect differing levels of conviction.